Related Experiment Video

Updated: Jul 1, 2026

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Pembrolizumab After Nephrectomy for High-risk Renal Cell Carcinoma: Real-world Data from a National Early Access

Idir Ouzaid1, Pierre Bigot1, Morgan Rouprêt1

  • 1National Cancer Committee of the National French Association of Urology, 17 rue Viète, Paris, France.

European Urology Oncology
|June 29, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Adjuvant therapyImmune checkpoint inhibitorPembrolizumabReal-world dataRenal cell carcinoma

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Experiment Videos

Last Updated: Jul 1, 2026

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Articles linked to this work by shared authors, journal, and citation graph.

Low diagnostic yield of routine preoperative chest CT in patients undergoing partial nephrectomy: A national cohort study using UroCCR data (UroCCR n°216).

BJUI compass·2026

Prognostic impact of tumor size in low-risk upper tract urothelial carcinoma: A multi-institutional analysis.

The French journal of urology·2026

Second-look transurethral resection in high-grade Ta non-muscle invasive bladder cancer.

World journal of urology·2026

A systematic review of gene-mediated therapy in BCG-unresponsive NMIBC: emerging evidence and future perspectives.

World journal of urology·2025

Initial Management and Reconstructive Surgery Algorithm for Fournier Gangrene.

Journal of plastic and reconstructive surgery·2025

Updated 2025 French guidelines for renal cell carcinoma.

The French journal of urology·2025

Risk-dependent Benefit of Adjuvant Pembrolizumab in High-risk Clear Cell Renal Cell Carcinoma: A Multi-institutional Study.

European urology oncology·2026

Feasibility and Characterization of Immune-related Pathologic Response Criteria in Renal Cell Carcinoma.

European urology oncology·2026

Gemcitabine-Cisplatin Chemotherapy Induces Nectin-4 Downregulation and Enfortumab Vedotin Resistance in Bladder Cancer.

European urology oncology·2026

Transdermal Estradiol for Treating Prostate Cancer: Revisiting Huggins and Hodges' Revolutionary Breakthrough.

European urology oncology·2026

Long-term Oncological Outcomes of Retzius-sparing Versus Anterior Robot-assisted Radical Prostatectomy: Post Hoc Analysis of a Randomized Cohort.

European urology oncology·2026

Long-term Prediction of Metastatic Recurrence in Patients Candidate to Radical Prostatectomy Using MRI and Targeted Biopsy: Insights into Tumor Zonal Origin.

European urology oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us